查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1769726

2025年全球紫斑治療市場報告

Purpura Treatment Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年紫斑治療市場規模將強勁成長。 2029年，該市場規模將成長至21.2億美元，複合年成長率為8.7%。未來市場發展的驅動力將包括：生物療法的發展、基因篩檢需求的不斷成長、對遠端醫療進行早期診斷的日益依賴、罕見疾病治療的監管激勵措施以及向個人化治療方法的轉變。預測期內的主要趨勢包括基因治療方法的進步、細胞療法的創新、精準藥物傳輸技術、穿戴式診斷工具的普及以及基於奈米技術的醫學的進步。

自體免疫疾病的日益普及預計將推動紫斑治療市場的擴張。當人類免疫系統將自體健康細胞和組織誤認為有害入侵者（例如細菌或病毒）時，就會引發自體免疫疾病。環境因素通常會促進發炎和分子模擬，從而導致免疫系統攻擊自身組織，增加自體免疫疾病的風險。紫斑治療在自體免疫疾病的管理中發揮關鍵作用，它可以抑制過度的免疫反應，促進血小板生成，並減少血管發炎。這有助於減輕瘀傷、出血和血小板計數低等症狀，這些症狀在自體免疫免疫性血小板缺乏紫斑症(ITP)）中很常見。例如，根據英國政府部門健康改善與差異辦公室2023年3月發布的報告，2022年16歲以上人群中17.6%報告患有長期肌肉骨骼系統（MSK）疾病，高於2021年的17.0%。因此，自體免疫疾病盛行率的上升正在推動紫斑治療市場的成長。

個人化醫療需求的不斷成長也有望推動紫斑治療市場的發展。個人化醫療是指根據患者的遺傳易感性、環境因素和生活方式，為其量身定做治療方案和干涉措施。基因組學和生物技術的進步推動了這一需求，使得根據個別基因圖譜進行更精準、更有效的治療成為可能，最終改善患者預後並最大限度地減少副作用。在紫斑治療領域，個人化醫療利用基因和免疫系統數據來客製化治療方案，根據患者獨特的生物反應提高療效並減少副作用。例如，根據美國專業會員組織個人化醫療聯盟 (Coalition for Personalized Medicine) 的數據，到 2022 年，新核准的12 種個人化醫療將佔當年所有新核准治療方法的約 34%，較前幾年顯著成長。因此，人們對個人化醫療日益成長的興趣正在推動紫斑治療市場的擴張。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球紫斑治療：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球紫斑治療市場：成長率分析
  • 全球紫斑治療市場表現：規模與成長，2019-2024 年
  • 全球紫斑治療市場預測：2024-2029 年及 2034 年規模與成長
  • 全球紫斑治療：總目標市場（TAM）

第6章市場區隔

  • 全球紫斑治療市場：依類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 非血小板減少性紫斑
  • 血小板減少性紫斑
  • 過敏性紫斑
  • 全球紫斑治療市場（依治療類型、表現及預測），2019-2024 年、2024-2029 年、2034 年
  • 局部治療
  • 口服藥物
  • 玻璃體內注射
  • 雷射治療
  • 動態療法
  • 全球紫斑治療市場（依病例、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 急性
  • 慢性的
  • 全球紫斑治療市場：依通路、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院藥房
  • 網路藥局
  • 零售藥局
  • 全球紫斑治療市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診所
  • 其他最終用戶
  • 全球紫斑治療市場依非血小板減少性紫斑症類型細分、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 特發性紫斑
  • 老年性紫斑
  • 紫斑性血管異常
  • 全球紫斑治療市場依血小板減少性紫斑症疾病類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 免疫性血小板減少性紫斑症（ITP）
  • 藥物性血小板減少性紫斑
  • 次發性紫斑
  • 全球紫斑治療市場按過敏性紫斑症類型細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 藥物性過敏性紫斑
  • 食物引起的過敏性紫斑
  • 感染相關過敏性紫斑

第7章 區域和國家分析

  • 全球紫斑治療市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球紫斑治療市場：依國家、地區、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

  • 紫斑治療市場：競爭格局
  • 紫斑治療市場：公司簡介
    • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

  • CSL Limited
  • Intas Pharmaceuticals Ltd.
  • Biogen Inc.
  • Chugai Pharmaceutical Co Ltd.
  • Sun Pharmaceutical Industries Limited
  • Octapharma AG
  • Grifols SA
  • GC Pharma
  • Emergent BioSolutions Inc.
  • Kissei Pharmaceutical Co Ltd.
  • Ablynx NV
  • Shire plc
  • Lee's Pharmaceutical Holdings Limited
  • Omeros Corporation
  • KM Biologics Co Ltd.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

  • 2029年紫斑治療市場：提供新機會的國家
  • 2029 年紫斑治療市場：細分領域帶來新機會
  • 2029 年紫斑症治療市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r36043

Purpura treatment refers to the medical care and management of purpura, which are purple-colored spots or patches on the skin caused by small blood vessels leaking under the skin. Purpura treatment is utilized by healthcare providers to manage symptoms and address underlying conditions such as platelet disorders, infections, or autoimmune diseases that cause bleeding under the skin.

The main types of purpura treatment include non-thrombocytopenic purpura, thrombocytopenic purpura, and allergic purpura. Non-thrombocytopenic purpura is characterized by bleeding under the skin, resulting in red or purple discoloration (purpura). These conditions are managed through different treatment approaches, such as topical therapies, oral medications, intravitreal injections, laser treatments, and photodynamic therapy. Purpura may present as either acute or chronic cases and is distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by various end users, such as hospitals, clinics, and other healthcare facilities.

The purpura treatment market research report is one of a series of new reports from The Business Research Company that provides purpura treatment market statistics, including purpura treatment industry global market size, regional shares, competitors with a purpura treatment market share, purpura treatment market segments, market trends and opportunities, and any further data you may need to thrive in the purpura treatment industry. This purpura treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The purpura treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The historical growth has been driven by the introduction of new therapeutic options, increased use of corticosteroids, growth in clinical research initiatives, rising healthcare expenditure, and improvements in hospital facilities.

The purpura treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Future market expansion will be fueled by the development of biologic therapies, rising demand for genetic screening, increased reliance on telehealth for early diagnosis, regulatory incentives for rare disease treatments, and a shift toward customized treatment approaches. Key trends anticipated during the forecast period include progress in gene-based therapies, innovations in cell therapy, precision drug delivery technologies, adoption of wearable diagnostic tools, and advancements in nanotechnology-based medicine.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the purpura treatment market. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells and tissues, believing they are harmful invaders such as bacteria or viruses. Environmental triggers often contribute to this by promoting inflammation or molecular mimicry, which leads the immune system to attack the body's own tissues and increases the risk of autoimmune diseases. Treatments for purpura play a crucial role in managing autoimmune diseases by suppressing the overactive immune response, enhancing platelet production, and reducing inflammation in blood vessels. This helps control symptoms like bruising, bleeding, and low platelet counts, which are commonly seen in autoimmune-related purpura such as immune thrombocytopenic purpura (ITP). For example, in March 2023, a report published by the Office for Health Improvement & Disparities, a UK government department, stated that in 2022, 17.6% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition, an increase from 17.0% in 2021. Thus, the rise in autoimmune disease prevalence is fueling the growth of the purpura treatment market.

The increasing demand for personalized medicine is also expected to boost the purpura treatment market. Personalized medicine involves tailoring medical treatments and practices to individual patients based on their genetic makeup, environmental factors, and lifestyle. This demand is being driven by advances in genomics and biotechnology, which allow for more precise and effective treatments tailored to individual genetic profiles, ultimately improving patient outcomes and minimizing side effects. In the context of purpura, personalized medicine uses genetic and immune system data to customize therapies, thereby improving treatment effectiveness and reducing adverse effects for patients based on their unique biological responses. For instance, according to the Personalized Medicine Coalition, a U.S.-based professional membership organization, in 2022, 12 newly approved personalized medicines accounted for approximately 34% of all new therapies approved that year, reflecting significant growth from previous years. Therefore, the growing interest in personalized medicine is contributing to the expansion of the purpura treatment market.

Leading companies in the purpura treatment market are prioritizing advancements in therapeutic options such as oral spleen tyrosine kinase (SYK) inhibitors to enhance treatment outcomes. These oral SYK inhibitors are medications that block the SYK enzyme, which plays a key role in the immune system's signaling processes. For example, in April 2023, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, introduced TAVALISSE tablets (100 mg and 150 mg) in Japan as an oral treatment for adult patients with chronic idiopathic thrombocytopenic purpura (ITP). TAVALISSE (fostamatinib sodium hydrate) works by inhibiting the destruction of platelets by macrophages, thus improving bleeding symptoms in chronic ITP patients. It was approved in Japan following a Phase 3 clinical trial (R788-1301), where 36% of patients achieved a stable platelet response compared to 0% in the placebo group, demonstrating its effectiveness as a new treatment option.

Major players in the purpura treatment market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Limited, Intas Pharmaceuticals Ltd., Biogen Inc., Chugai Pharmaceutical Co Ltd., Sun Pharmaceutical Industries Limited, Octapharma AG, Grifols S.A., GC Pharma, Emergent BioSolutions Inc., Kissei Pharmaceutical Co Ltd., Ablynx N.V., Shire plc, Lee's Pharmaceutical Holdings Limited, Omeros Corporation, and KM Biologics Co Ltd.

North America was the largest region in the purpura treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in purpura treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the purpura treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The purpura treatment market consists of revenues earned by entities by providing services such as diagnostic evaluations, immunosuppressive therapy, intravenous immunoglobulin (IVIG) infusions, platelet transfusions, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The purpura treatment market also includes sales of products including corticosteroids, immunoglobulins (IVIG), biologics, immunosuppressants, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Purpura Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on purpura treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for purpura treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The purpura treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Non-Thrombocytopenic Purpura; Thrombocytopenic Purpura; Allergic Purpura
  • 2) By Treatment Type: Topical Treatments; Oral Medications; Intravitreal Injections; Laser Therapy; Photodynamic Therapy
  • 3) By Cases: Acute; Chronic
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End-User: Hospitals; Clinics; Other End-Users
  • Subsegments:
  • 1) By Non-Thrombocytopenic Purpura: Idiopathic Purpura; Senile Purpura; Vascular Abnormalities
  • 2) By Thrombocytopenic Purpura: Immune Thrombocytopenic Purpura (ITP); Drug-induced Thrombocytopenic Purpura; Secondary Thrombocytopenic Purpura
  • 3) By Allergic Purpura: Drug-induced Allergic Purpura; Food-induced Allergic Purpura; Infectious-related Allergic Purpura
  • Companies Mentioned: Merck & Co Inc.; Sanofi S.A.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Amgen Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Purpura Treatment Market Characteristics

3. Purpura Treatment Market Trends And Strategies

4. Purpura Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Purpura Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Purpura Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Purpura Treatment Market Growth Rate Analysis
  • 5.4. Global Purpura Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Purpura Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Purpura Treatment Total Addressable Market (TAM)

6. Purpura Treatment Market Segmentation

  • 6.1. Global Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Thrombocytopenic Purpura
  • Thrombocytopenic Purpura
  • Allergic Purpura
  • 6.2. Global Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Topical Treatments
  • Oral Medications
  • Intravitreal Injections
  • Laser Therapy
  • Photodynamic Therapy
  • 6.3. Global Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acute
  • Chronic
  • 6.4. Global Purpura Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Purpura Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Other End-Users
  • 6.6. Global Purpura Treatment Market, Sub-Segmentation Of Non-Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Idiopathic Purpura
  • Senile Purpura
  • Purpura Vascular Abnormalities
  • 6.7. Global Purpura Treatment Market, Sub-Segmentation Of Thrombocytopenic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immune Thrombocytopenic Purpura (ITP)
  • Drug-induced Thrombocytopenic Purpura
  • Secondary Thrombocytopenic Purpura
  • 6.8. Global Purpura Treatment Market, Sub-Segmentation Of Allergic Purpura, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drug-Induced Allergic Purpura
  • Food-Induced Allergic Purpura
  • Infectious-related Allergic Purpura

7. Purpura Treatment Market Regional And Country Analysis

  • 7.1. Global Purpura Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Purpura Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Purpura Treatment Market

  • 8.1. Asia-Pacific Purpura Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Purpura Treatment Market

  • 9.1. China Purpura Treatment Market Overview
  • 9.2. China Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Purpura Treatment Market

  • 10.1. India Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Purpura Treatment Market

  • 11.1. Japan Purpura Treatment Market Overview
  • 11.2. Japan Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Purpura Treatment Market

  • 12.1. Australia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Purpura Treatment Market

  • 13.1. Indonesia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Purpura Treatment Market

  • 14.1. South Korea Purpura Treatment Market Overview
  • 14.2. South Korea Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Purpura Treatment Market

  • 15.1. Western Europe Purpura Treatment Market Overview
  • 15.2. Western Europe Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Purpura Treatment Market

  • 16.1. UK Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Purpura Treatment Market

  • 17.1. Germany Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Purpura Treatment Market

  • 18.1. France Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Purpura Treatment Market

  • 19.1. Italy Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Purpura Treatment Market

  • 20.1. Spain Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Purpura Treatment Market

  • 21.1. Eastern Europe Purpura Treatment Market Overview
  • 21.2. Eastern Europe Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Purpura Treatment Market

  • 22.1. Russia Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Purpura Treatment Market

  • 23.1. North America Purpura Treatment Market Overview
  • 23.2. North America Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Purpura Treatment Market

  • 24.1. USA Purpura Treatment Market Overview
  • 24.2. USA Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Purpura Treatment Market

  • 25.1. Canada Purpura Treatment Market Overview
  • 25.2. Canada Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Purpura Treatment Market

  • 26.1. South America Purpura Treatment Market Overview
  • 26.2. South America Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Purpura Treatment Market

  • 27.1. Brazil Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Purpura Treatment Market

  • 28.1. Middle East Purpura Treatment Market Overview
  • 28.2. Middle East Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Purpura Treatment Market

  • 29.1. Africa Purpura Treatment Market Overview
  • 29.2. Africa Purpura Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Purpura Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Purpura Treatment Market, Segmentation By Cases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Purpura Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Purpura Treatment Market Competitive Landscape
  • 30.2. Purpura Treatment Market Company Profiles
    • 30.2.1. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Purpura Treatment Market Other Major And Innovative Companies

  • 31.1. CSL Limited
  • 31.2. Intas Pharmaceuticals Ltd.
  • 31.3. Biogen Inc.
  • 31.4. Chugai Pharmaceutical Co Ltd.
  • 31.5. Sun Pharmaceutical Industries Limited
  • 31.6. Octapharma AG
  • 31.7. Grifols S.A.
  • 31.8. GC Pharma
  • 31.9. Emergent BioSolutions Inc.
  • 31.10. Kissei Pharmaceutical Co Ltd.
  • 31.11. Ablynx N.V.
  • 31.12. Shire plc
  • 31.13. Lee's Pharmaceutical Holdings Limited
  • 31.14. Omeros Corporation
  • 31.15. KM Biologics Co Ltd.

32. Global Purpura Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Purpura Treatment Market

34. Recent Developments In The Purpura Treatment Market

35. Purpura Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Purpura Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Purpura Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Purpura Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer